Navigation Links
Drug-eluting stents safe, effective for treatment of chronic total occlusions
Date:9/21/2009

SAN FRANCISCO, CA SEPTEMBER 21, 2009 A multicenter study in Asia found drug-eluting stents effective with a low rate of acute complications in patients with chronic total occlusions (CTOs) undergoing PCI. Results of the study will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

The aim of the study, "Drug-Eluting Stents for the Treatment of Chronic Total Occlusion: A Comparison with Sirolimus (SES), Paclitaxel (PES), Zotarolimus (ZES), Biolimus A9 (BES), EPC Capture (ECS) and Everolimus-Eluting Stent (EES): Multicenter Registry in Asia" is to compare the safety and efficacy of SES, PES, ZES, BES, SCS and EES in the treatment of patients with chronic total occlusion (blockage) of cardiac blood vessels. The study will be presented as a poster abstract (TCT-234) on Tuesday, September 22 between 8:00 a.m. and 10:00 a.m. in Hall D of The Moscone Center.

For the study, researchers led by Sunao Nakamura, MD, performed a prospective analysis of 1,148 patients with 1,253 CTOs treated with different drug-eluting stents (396 SES, 526 PES, 177 ZES, 66 BES, 41 ECS, and 43 EES) in six high volume Asian centers after successful CTO re-canalization was performed.

Dr. Nakamura, who will report on the results of the investigations, is Vice President and Director of the Cardiovascular Center at New Tokyo Hospital as well as Clinical and Visiting Professor of Kumamoto University in Matsudo, Japan.

The researchers found that the incidence of major adverse cardiac events (MACE) at 30 days was nearly non-existent in patients with CTO lesions treated with drug-eluting stents (0.4% in patients with PES, 0.6% in ZES and 0% in all other categories). MACE at 9 months was 3.6% for those receiving SES, 6.7% for PES, 10.4% for ZES, 4.5% for BES, 10.3% for ECS and 2.4% for EES. Target lesion revascularization (TLR) at 9 months was 3.6% for patients who received SES, 6.7% for PES, 10.4% for ZES, 4.5% for BES, 10.3% for ECS and 2.4% for EES.

In addition, patients treated with SES, BES and EES showed a lesser rate of angiographic restenosis compared with other drug-eluting stents at 9 months (4.0% restenosis for patients receiving SES, 6.7% for PES, 12.3% for ZES, 4.5% for BES, 10.3% for ECS and 2.4% for EES).

In conclusion, Dr. Nakamura noted that, "The study indicates a good clinical performance of the new BES and EES devices."


'/>"/>

Contact: Judy Romero
jromero@crf.org
347-407-2774
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Researchers find drug-eluting stents safe, effective for PCI in diabetics
2. Analysis of drug-eluting stents data demonstrates safety, efficacy in on-and-off-label use
3. NEJM study finds drug-eluting stents more effective than bare-metal stents in heart attack patients
4. CorNova to Present at the Glimpse into the Future: Emerging Drug-Eluting Stents Symposium at EuroPCR 2009
5. No Increase in Clots With Drug-Eluting Stents
6. Drug-eluting stents found safe, superior to bare metal stents
7. XTENT Receives CE Mark Approval for CUSTOM NX (R) Drug-Eluting Stent System
8. Drug-Eluting Stents Show Promise for Leg Arteries
9. Promising Three-year Data: Saving Limbs With Drug-Eluting Stents
10. Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System
11. SYNTAX defines borders between CABG and PCI with TAXUS drug-eluting stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... ... “Cursed with a Curse: The Truth about Tithing”: a ... when breaking free from this misconception. “Cursed with a Curse: The Truth about ... Christian Faith Publishing, Lysa M. Harrison’s new book is a powerful and thought-provoking ...
(Date:9/22/2017)... ... ... “Fruit of the Spirit: “Love””: a delightful adventure of two friends who ... the Spirit: “Love”” is the creation of published author, Halimah Jones, who was born ... is an avid writer, her inspiration for “Fruit of the Spirit: “Love”” blossomed from ...
(Date:9/21/2017)... ... September 21, 2017 , ... With ProSlideshow Portrait from ... easy to do. Users can select from up to two layers of subject matter ... of a mouse all within Final Cut Pro X. , With ProSlideshow ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... ... **An FDAnews Management Report**, http://www.fdanews.com/products/54818-promotional-communication      , In the competitive world of ... can get while staying in compliance with FDA rules. , The FDA has ...
(Date:9/21/2017)... ... September 21, 2017 , ... Innovatum ... at the Global GS1 Healthcare Conference 2017 in Chicago, IL on October 17-19, ... ensuring label quality and improving patient safety. , Microscan , a ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... -- Dealmed Medical Supplies, New York City,s ... drugs, vaccines, and specialty medical products and services, announced ... acquire Vantage Medical Supplies, a major distributor of medical ... York . ... practices, will operate under the Dealmed name as of ...
(Date:9/7/2017)... , Sept. 7, 2017  For nearly two decades, New Life Agency ... Assisted Reproduction Insurance industry. Today, New Life Agency announces a powerful three-way ... ... ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
(Date:9/7/2017)... 7, 2017  Zimmer Biomet Holdings, Inc. (NYSE and ... announced that it will be participating in the Morgan ... the Grand Hyatt hotel in New York.  Zimmer Biomet ... a.m. Eastern Time. A live webcast of ... Relations website at http://investor.zimmerbiomet.com .   ...
Breaking Medicine Technology: